Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial

What Was Tested

Researchers studied Glutathione in the context of mitochondrial dysfunction in this randomized controlled trial publication.

Who Took Part

According to the abstract, 12 adults were involved.

PubMed indexes the participants as older adults.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this Glutathione study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Glutathione group a baseline to be compared against.

A time span of 16 weeks appears in the methods.

OA was randomized to receive either GlyNAC (N = 12) or isonitrogenous alanine placebo (N = 12) for 16-weeks; YA (N = 12) received GlyNAC for 2-weeks.

What Was Measured

PubMed files the paper under topics including Mice, Acetylcysteine, Glycine, Health Promotion, Oxidative Stress, Aging and Glutathione.

Author keywords: Clinical trials, GlyNAC, Metabolism and Successful aging.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Glutathione in 12 adults in people with mitochondrial dysfunction over 16 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (The journals of gerontology. Series A, Biological sciences and medical sciences), a journal based in United States.

More context: the Glutathione compound page, Mitochondrial dysfunction research.